Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed to treat type 2 diabetes
In the case of glutathione, you want to know how it will get inside cells or bypass known bottlenecks in cellular glutathione production
The increased frequency of DKA observed in this subpopulation can be explained by the renal and pancreatic effects of SGLT2-inhibitors that are emphasized in patients in therapy with insulin, since to minimize the risk of hypoglycaemia it is necessary to further decrease the insulin dose
T., Ledesma, B., Ghomeshi, A., Jara-Palacios, M
Lu H, Xiao H, Dai M, Xue Y, Zhao R